Home
About
R & D
Efruxifermin
- Efruxifermin Publications
What is Nash?
Contact
Terms of Use
Menu Menu

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

March 4, 2020/in Publications /by David Anderson

Share this entry

Share on Facebook
Share on Twitter
Share on WhatsApp
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2020-03-04 11:14:072020-03-04 11:14:07Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

About
R & D
Efruxifermin
- Efruxifermin Publications
Investors
What is Nash?
Contact

© 2021 Akero Therapeutics, Inc. All rights reserved. Terms of Use.

Scroll to top